Malignant mesothelioma treated with immune checkpoint inhibitors with or without cancer vaccine (the NIPU-study) Updates
The trial has completed accrual and randomised 118 patients.
A total of 109 patients are included in the trial. Only 9 patients remain to be included before completion of 118 patients.
Rigshospitalet, Copenhagen, Denmark, has been initiated as study site
Val d’Hebron, Barcelona, Spain, has been initiated as study site
Publication on the NIPU-trial in Journal of Translational Medicine
Karolinska Institutet, Stockholm, Sweden, has been initiated as study site
Aalborg University Hospital, Ålborg, Denmark, has been initiated as study site
University of Western Australia, Perth, is now initiated as a sight and will shortly start inclusion of patients
Oslo University Hospital started inclusion in May 2020. Other sites are expected to start inclusion in November 2020.